320 related articles for article (PubMed ID: 12872341)
1. High-dose 131I-metaiodobenzylguanidine therapy for 12 patients with malignant pheochromocytoma.
Rose B; Matthay KK; Price D; Huberty J; Klencke B; Norton JA; Fitzgerald PA
Cancer; 2003 Jul; 98(2):239-48. PubMed ID: 12872341
[TBL] [Abstract][Full Text] [Related]
2. Malignant pheochromocytomas and paragangliomas: a phase II study of therapy with high-dose 131I-metaiodobenzylguanidine (131I-MIBG).
Fitzgerald PA; Goldsby RE; Huberty JP; Price DC; Hawkins RA; Veatch JJ; Dela Cruz F; Jahan TM; Linker CA; Damon L; Matthay KK
Ann N Y Acad Sci; 2006 Aug; 1073():465-90. PubMed ID: 17102115
[TBL] [Abstract][Full Text] [Related]
3. Low-dose iodine-131 metaiodobenzylguanidine therapy for patients with malignant pheochromocytoma and paraganglioma: single center experience.
Shilkrut M; Bar-Deroma R; Bar-Sela G; Berniger A; Kuten A
Am J Clin Oncol; 2010 Feb; 33(1):79-82. PubMed ID: 19704370
[TBL] [Abstract][Full Text] [Related]
4. Phase II study of high-dose [131I]metaiodobenzylguanidine therapy for patients with metastatic pheochromocytoma and paraganglioma.
Gonias S; Goldsby R; Matthay KK; Hawkins R; Price D; Huberty J; Damon L; Linker C; Sznewajs A; Shiboski S; Fitzgerald P
J Clin Oncol; 2009 Sep; 27(25):4162-8. PubMed ID: 19636009
[TBL] [Abstract][Full Text] [Related]
5. [131I]metaiodobenzylguanidine therapy in 20 patients with malignant pheochromocytoma.
Lumbroso J; Schlumberger M; Tenenbaum F; Aubert B; Travagli JP; Parmentier C
J Nucl Biol Med (1991); 1991; 35(4):288-91. PubMed ID: 1823838
[TBL] [Abstract][Full Text] [Related]
6. Repeated [131I]metaiodobenzylguanidine therapy in two patients with malignant pheochromocytoma.
Lam MG; Lips CJ; Jager PL; Dullaart RP; Lentjes EG; van Rijk PP; de Klerk JM
J Clin Endocrinol Metab; 2005 Oct; 90(10):5888-95. PubMed ID: 16046591
[TBL] [Abstract][Full Text] [Related]
7. Nuclear medicine therapy of pheochromocytoma and paraganglioma.
Troncone L; Rufini V
Q J Nucl Med; 1999 Dec; 43(4):344-55. PubMed ID: 10731785
[TBL] [Abstract][Full Text] [Related]
8. [131I]metaiodobenzylguanidine therapy of malignant pheochromocytoma: interference of medication.
Hoefnagel CA; Schornagel J; Valdés Olmos RA
J Nucl Biol Med (1991); 1991; 35(4):308-12. PubMed ID: 1823843
[TBL] [Abstract][Full Text] [Related]
9. Treatment of malignant pheochromocytoma with [131I]metaiodobenzylguanidine: a French multicenter study.
Krempf M; Lumbroso J; Mornex R; Brendel AJ; Wemeau JL; Delisle MJ; Aubert B; Carpentier P; Fleury-Goyon MC; Gibold C
J Nucl Biol Med (1991); 1991; 35(4):284-7. PubMed ID: 1823837
[TBL] [Abstract][Full Text] [Related]
10. Radiopharmaceutical therapy of malignant pheochromocytoma with [131I]metaiodobenzylguanidine: results from ten years of experience.
Shapiro B; Sisson JC; Wieland DM; Mangner TJ; Zempel SM; Mudgett E; Gross MD; Carey JE; Zasadny KR; Beierwaltes WH
J Nucl Biol Med (1991); 1991; 35(4):269-76. PubMed ID: 1823834
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of [131I]metaiodobenzylguanidine therapy for patients with refractory neuroblastoma.
Matthay KK; Huberty JP; Hattner RS; Ablin AR; Engelstad BL; Zoger S; Hasegawa BH; Price D
J Nucl Biol Med (1991); 1991; 35(4):244-7. PubMed ID: 1823827
[TBL] [Abstract][Full Text] [Related]
12. Phase II study on the effect of disease sites, age, and prior therapy on response to iodine-131-metaiodobenzylguanidine therapy in refractory neuroblastoma.
Matthay KK; Yanik G; Messina J; Quach A; Huberty J; Cheng SC; Veatch J; Goldsby R; Brophy P; Kersun LS; Hawkins RA; Maris JM
J Clin Oncol; 2007 Mar; 25(9):1054-60. PubMed ID: 17369569
[TBL] [Abstract][Full Text] [Related]
13. Phase I dose escalation of iodine-131-metaiodobenzylguanidine with myeloablative chemotherapy and autologous stem-cell transplantation in refractory neuroblastoma: a new approaches to Neuroblastoma Therapy Consortium Study.
Matthay KK; Tan JC; Villablanca JG; Yanik GA; Veatch J; Franc B; Twomey E; Horn B; Reynolds CP; Groshen S; Seeger RC; Maris JM
J Clin Oncol; 2006 Jan; 24(3):500-6. PubMed ID: 16421427
[TBL] [Abstract][Full Text] [Related]
14. Clinical and pathological data of 10 malignant pheochromocytomas: long-term follow up in a single institute.
Huang KH; Chung SD; Chen SC; Chueh SC; Pu YS; Lai MK; Lin WC
Int J Urol; 2007 Mar; 14(3):181-5. PubMed ID: 17430251
[TBL] [Abstract][Full Text] [Related]
15. Arsenic Trioxide as a Radiation Sensitizer for 131I-Metaiodobenzylguanidine Therapy: Results of a Phase II Study.
Modak S; Zanzonico P; Carrasquillo JA; Kushner BH; Kramer K; Cheung NK; Larson SM; Pandit-Taskar N
J Nucl Med; 2016 Feb; 57(2):231-7. PubMed ID: 26742708
[TBL] [Abstract][Full Text] [Related]
16. The treatment of malignant pheochromocytoma with iodine-131 metaiodobenzylguanidine (131I-MIBG): a comprehensive review of 116 reported patients.
Loh KC; Fitzgerald PA; Matthay KK; Yeo PP; Price DC
J Endocrinol Invest; 1997 Dec; 20(11):648-58. PubMed ID: 9492103
[TBL] [Abstract][Full Text] [Related]
17. Tumor response and toxicity with multiple infusions of high dose 131I-MIBG for refractory neuroblastoma.
Howard JP; Maris JM; Kersun LS; Huberty JP; Cheng SC; Hawkins RA; Matthay KK
Pediatr Blood Cancer; 2005 Mar; 44(3):232-9. PubMed ID: 15490487
[TBL] [Abstract][Full Text] [Related]
18. Management of metastatic phaeochromocytoma and paraganglioma: use of iodine-131-meta-iodobenzylguanidine therapy in a tertiary referral centre.
Rutherford MA; Rankin AJ; Yates TM; Mark PB; Perry CG; Reed NS; Freel EM
QJM; 2015 May; 108(5):361-8. PubMed ID: 25267727
[TBL] [Abstract][Full Text] [Related]
19. Combined use of chemotherapy and 131I-metaiodobenzylguanidine in the treatment of advanced-stage neuroblastoma.
Sari O; Uğur O; Emir S; Akyüz C
Turk J Pediatr; 2001; 43(1):29-33. PubMed ID: 11297155
[TBL] [Abstract][Full Text] [Related]
20. 131I-MIBG therapy of neural crest tumours (review).
Troncone L; Rufini V
Anticancer Res; 1997; 17(3B):1823-31. PubMed ID: 9179240
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
